Nemluvio Sustained Eczema Relief in Long-Term Study
Adults and adolescents saw lasting improvements in skin health and itch reduction over nearly three years.
Updated on Oct. 8, 2026 in Allergies
Live Poll
Does long-term clinical data make you more likely to trust new treatments for chronic skin conditions?
New data from a long-term clinical study show that patients with moderate-to-severe atopic dermatitis maintained clear skin and itch relief for up to 152 weeks while using the monoclonal antibody Nemluvio. The interim analysis included 1,903 patients and supports the durability of the treatment.
Why it matters
These findings provide long-term evidence on the safety and efficacy of the treatment for managing chronic skin inflammation and itch. For patients dealing with these persistent conditions, the study highlights the potential for sustained disease management.
In an analysis of 1,903 patients, researchers evaluated skin lesion and itch responses through a long-term extension study lasting 152 weeks. The results showed that 76 percent of patients achieved clear or almost clear skin by the end of the study.
The players
Galderma
A pharmaceutical company headquartered in Zug, Switzerland, that focuses on dermatology treatments and the development of Nemluvio.
The details
Nemluvio is a monoclonal antibody that works by inhibiting IL-31 signaling, a pathway associated with inflammation and itch in skin conditions. The study followed 295 patients who achieved an early clinical response by Week 16 and continued the treatment through maintenance and extension phases. This targeted inhibition helps calm the skin and reduce the urge to scratch, allowing for sustained quality-of-life improvements.
Timeline
2016: Galderma obtained exclusive development rights for nemolizumab.
March 27-31, 2026: Phase II pediatric data were presented at the AAD 2026 meeting.
October 8-11, 2026: The Fall Clinical Dermatology Conference was held in Las Vegas.
October 9, 2026: A Galderma-sponsored product theatre session took place.
Health Landscape
This data update fits into the broader evolution of targeted monoclonal antibodies for inflammatory skin diseases. It follows the pattern established by the ARCADIA long-term extension study in defining the potential for multi-year management of atopic dermatitis.
If you are managing moderate-to-severe atopic dermatitis or prurigo nodularis, these findings may be worth discussing with your doctor to understand long-term treatment expectations. Pay close attention to how your skin and itch levels evolve, as maintenance of these outcomes is key to long-term quality of life.
The takeaway
These findings show that targeted antibody therapy can provide sustained relief from skin lesions and itch for patients with chronic dermatitis. If you are exploring long-term treatment options, consult a dermatologist to track your disease severity and quality-of-life benchmarks over time.
Further reading
For more information on managing skin conditions, visit our Allergies section.
Live Poll
Does long-term clinical data make you more likely to trust new treatments for chronic skin conditions?
